Department of Dermatology, Queen's Medical Centre, Nottingham, U.K.
Leeds Beckett University, Leeds, U.K.
Br J Dermatol. 2018 Sep;179(3):609-614. doi: 10.1111/bjd.16796. Epub 2018 Jul 17.
CLINICAL QUESTION/SCENARIO: Is methotrexate (MTX) an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis?
Alopecia areata (AA) is a common disorder causing nonscarring hair loss with an estimated lifetime prevalence of approximately 2%. Treatment of extensive AA is challenging. The aim of this Critically Appraised Topic was to assess the current evidence regarding use of MTX for inducing and maintaining hair growth in patients with alopecia totalis.
We critically appraised the literature identified from searching PubMed, Ovid MEDLINE, Ovid Embase and Cochrane Central (October 2017), using the search terms ("alopecia areata" OR "alopecia totalis" OR "alopecia universalis") AND (methotrexate).
RESULTS/IDENTIFIED EVIDENCE: Two prospective studies and 11 retrospective case series were included, comprising 226 patients with alopecia varying from 30% hair loss to alopecia universalis at baseline. MTX was usually given with systemic corticosteroids for induction of hair regrowth rather than regrowth maintenance. Regrowth, defined as anything from 50% to complete regrowth, was reported in 20-90% of patients. Relapse occurred in 20-80%, with variable regrowth on retreatment. Most series were small, with limited methodological detail and follow-up data. Adverse effects ranged from 7% to 60%.
We found insufficient evidence to conclude whether MTX is useful for maintaining regrowth in extensive AA. We found some evidence to suggest that hair regrowth may be induced by MTX when used in combination with systemic corticosteroids, but it was difficult to attribute responses to any one treatment or spontaneous regrowth. Included case series were at a high risk of bias. Randomized controlled trials are needed to evaluate whether MTX alone, or in combination with corticosteroids, vs. placebo is useful for inducing and/or maintaining remission of hair regrowth. In the meantime, MTX may occasionally be considered in people with severe disease that significantly impacts on their quality of life.
临床问题/情境:甲氨蝶呤(MTX)是否是治疗全秃患者毛发再生的有效且安全的方法?
斑秃(AA)是一种常见的非瘢痕性脱发疾病,其终生患病率估计约为 2%。广泛 AA 的治疗具有挑战性。本专题评价旨在评估目前关于 MTX 诱导和维持全秃患者毛发生长的证据。
我们通过搜索 PubMed、Ovid MEDLINE、Ovid Embase 和 Cochrane Central(2017 年 10 月),使用检索词(“alopecia areata”或“alopecia totalis”或“alopecia universalis”)和(methotrexate),对文献进行了严格评价。
结果/确定的证据:共纳入 2 项前瞻性研究和 11 项回顾性病例系列研究,共纳入 226 例脱发患者,基线时脱发程度从 30%至全秃不等。MTX 通常与全身皮质类固醇联合用于诱导毛发生长,而非维持毛发生长。再生定义为 50%至完全再生,报告的患者比例为 20%至 90%。复发率为 20%至 80%,再次治疗时有不同程度的再生。大多数系列研究规模较小,方法学细节和随访数据有限。不良反应发生率为 7%至 60%。
我们发现没有足够的证据来确定 MTX 是否对广泛 AA 的毛发生长维持有效。我们发现一些证据表明,当 MTX 与全身皮质类固醇联合使用时,可能会诱导毛发生长,但很难将反应归因于任何一种治疗方法或自发再生。纳入的病例系列研究存在较高的偏倚风险。需要进行随机对照试验,以评估 MTX 单独或与皮质类固醇联合使用与安慰剂相比,是否对诱导和/或维持毛发生长缓解有效。在此期间,对于严重影响生活质量的严重疾病患者,偶尔可以考虑使用 MTX。